Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells.
This podcast features a discussion from the 2nd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPNs). Experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, share insights into the management of PV and ET. They focus on treating the adolescent and young adult (AYA) population, defining goals when treating patients, and the feasibility of assessing long-term outcomes in clinical trials. Additionally, they emphasize collaborative research approaches and explore the potential for early interventions at the stage of clonal hematopoiesis in AYA patients.
The post Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more appeared first on VJHemOnc.
